azilsartan

Azilsartan (TAK-536) is an Angiotensin 2 Receptor Blocker that acts as an Angiotensin 2 Type 1 Receptor Antagonist, leading to a physiologic effect of decreased blood pressure.

Azilsartan Medoxomil (TAK-491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

Azilsartan Medoxomil Potassium (TAK-491 Potassium) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

Azilsartan Methyl Ester is an angiotensin II receptor antagonist. Azilsartan Methyl Ester inhibits specific binding of [125I]AII (0.2 nM) to bovine adrenal cortex with IC50 value is 0.44uM.

Azilsartan mepixetil is a potent angiotensin II receptor antagonist with enhanced efficacy and prolonged duration of action. It exhibits more prominent and sustained effects in lowering blood pressure and heart rate, while maintaining a high level of safety. Furthermore, Azilsartan mepixetil demonstrates optimal protective efficacy for cardiovascular and renal functions. Hence, it holds promise for the research and treatment of hypertension, chronic heart failure, and diabetic nephropathy.

Azilsartan (TAK-536) D5 is the deuterium-labeled Azilsartan. Azilsartan is a specific antagonist of the angiotensin II type 1 receptor.

Azilsartan is an angiotensin II receptor antagonist for the treatment of hypertension and was developed by Takeda. Azilsartan Medoxomil lowers blood pressure by blocking the effects of angiotensin II, a type of vasopressin.

Azilsartan medoxomil potassium (QR-01019K), an angiotensin II receptor antagonist, exhibits a potent and sustained antihypertensive effect, along with a more pronounced and enduring reduction in heart rate, and a high safety profile. It shows promise for investigation in the management of hypertension, chronic heart failure, and diabetic nephropathy[1].

Azilsartan medoxomil is a potent antagonist of the angiotensin II receptor (AT1).